» Articles » PMID: 17635074

Reproducibility of Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG) Classification: a Systematic Review

Overview
Specialties Biochemistry
Pathology
Date 2007 Jul 20
PMID 17635074
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The classifications of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) represent glucose levels above normal, but below the decision threshold for diabetes. We sought to determine what the reproducibility of these classifications was when repeat tests were performed by conducting a systematic review of the literature.

Methods: All primary studies published in English of any study design were included. Studies were excluded if they did not follow the World Health Organization or American Diabetes Association diagnostic criteria, used whole blood as the specimen type, a glucose meter for analysis, or performed repeat testing greater than 8 weeks apart.

Results: Five papers had reproducibility data for IGT or IFG, two of which where from the same population but sampled differently. The kappa coefficients, indicating agreement between repeat tests that exceeded chance, indicated poor to fair agreement for IGT (0.04, 0.22, 0.38, 0.42) and moderate agreement for IFG (0.44 and 0.56). Similarly, the observed reproducibility was slightly lower for IGT (33%, 44%, 47%, 48%) compared to IFG (51%, 64%). In two studies for which data were available for both IGT and IFG, the average reproducibility was lower (49%) for the prediabetes group compared to the diabetes group (73%) or the normal group (93%).

Conclusions: Poor reproducibility of IGT and IFG classification suggests caution should be exercised when interpreting a single test result.

Citing Articles

Continuous glucose monitoring and intrapersonal variability in fasting glucose.

Shilo S, Keshet A, Rossman H, Godneva A, Talmor-Barkan Y, Aviv Y Nat Med. 2024; 30(5):1424-1431.

PMID: 38589602 DOI: 10.1038/s41591-024-02908-9.


The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis.

Kirigin Bilos L, Altabas V, Vukic Dugac A, Baretic M Medicina (Kaunas). 2024; 60(3).

PMID: 38541202 PMC: 10972086. DOI: 10.3390/medicina60030477.


Application of Clinical Blood Metabogram to Type 2 Diabetes Mellitus.

Lokhov P, Balashova E, Trifonova O, Maslov D, Shestakova E, Shestakova M Metabolites. 2024; 14(3).

PMID: 38535328 PMC: 10972189. DOI: 10.3390/metabo14030168.


Differential contribution of alpha and beta cell dysfunction to impaired fasting glucose and impaired glucose tolerance.

Kohlenberg J, Laurenti M, Egan A, Schembri Wismayer D, Bailey K, Cobelli C Diabetologia. 2022; 66(1):201-212.

PMID: 36112169 PMC: 9742343. DOI: 10.1007/s00125-022-05794-3.


Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.

Scully K, Sherwood J, Martin K, Ruazol M, Marchetti P, Larkin M J Clin Endocrinol Metab. 2021; 107(4):e1444-e1454.

PMID: 34850006 PMC: 8947309. DOI: 10.1210/clinem/dgab857.